Evaluation of D-Fi for the Treatment of Wounds Due to DEB
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
Active, not recruiting · NCT06892639 · Registry updated 2026-03-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of D-Fi for the Treatment of Wounds Due to DEB | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, hereditary disease, hereditary skin disorder, skin disorder, vesiculobullous skin disease | Active, not recruiting | Phase 3 | 2026-03-13 | NCT06892639 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Castle Creek Biosciences, LLC. | 2 |
| Prosoft Clinical | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital Colorado | Aurora | United States | 312 |
| Mission Dermatology | Santa Margarita | United States | 1 |
| Stanford University School of Medicine, Dermatology | Redwood City | United States | 1 |
| University of Massachusetts | Worcester | United States | 16 |